The Role of the Complement Cascade in Ischemia/Reperfusion Injury: Implications for Neuroprotection

Molecular Medicine

Volumn 7, Issue 6, 2001, Pages 367-382

  D'Ambrosio, Anthony L ^a   Pinsky, David J ^a   Connolly, E Sander ^a  

^a NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT INHIBITOR; NEUROPROTECTIVE AGENT;

ANIMAL; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMPLEMENT ACTIVATION; DISEASE MODEL; HUMAN; IMMUNOLOGY; METABOLISM; NERVE CELL; PATHOPHYSIOLOGY; REPERFUSION INJURY; REVIEW;

ANIMALS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATOR PROTEINS; DISEASE MODELS, ANIMAL; HUMANS; NEURONS; NEUROPROTECTIVE AGENTS; REPERFUSION INJURY;

EID: 0035376112     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03402183     Document Type: Article

References (144)

1. del Zoppo G, Ginis I, Hallenbeck JM, Iadecola C, Wang X, Feuerstein GZ. (2000) Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol. 10: 95-112.
2. Foreman KE, Glovsky MM, Warner RL, Horvath SJ, Ward PA. (1996) Comparative effect of C3a and C5a on adhesion molecule expression on neutrophils and endothelial cells. Inflammation 20: 1-9.
3. Pemberton M, Anderson G, VetVicka V, Justus DE, Ross GD. (1993) Microvascular effects of complement blockade with soluble recombinant CR1 on ischemia/reperfusion injury of skeletal muscle. J. Immunol. 11: 5104-5113.
4. Hill J, Lindsay TF, Ortiz F, Yeh CG, Hechtman HB, Moore, FD Jr. (1992) Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat. J. Immunol. 149: 1723-1728.
5. Ikai M, Itoh M, Joh T, Yokoyama Y, Okada N, Okada H. (1996) Complement plays an essential role in shock following intestinal ischemia in rats. Clin. Exp. Immunol. 106: 156-159.
6. Chavez-Cartaya RE, DeSola GP, Wright L, Jamieson NV, White DJ. (1995) Regulation of the complement cascade by soluble complement receptor type 1. Protective effect in experimental liver ischemia and reperfusion. Transplantation 59: 1047-1052.
7. Zamora MR, Davis RD, Keshavjee SH, et al. (2000) Complement inhibition attenuates human lung transplant reperfusion injury: a multicenter trial. Chest 116: 46S.
8. Hill JH, Ward PA. (1971) The phlogistic role of C3 leukotactic fragments in myucardial infarct of rats. J. Exp. Med. 133: 885-900.
9. Kato H, Kogure K. (1999) Biochemical and molecular characteristics of the brain with developing cerebral infarction. [Review]. Cell. Mol. Neurobiol. 19: 93-108.
10. Dawson DA, Ruetzler CA, Carlos TM, Kochanek PM, Hallenbeck JM. (1996) Polymorphonuclear leukocytes and microcirculatory perfusion in acute stroke in the SHR. Keio J. Med 45: 248-252.
11. del Zoppo GJ, Schmid-Schonbein GW, Mori E, Copeland BR, Chang C. (1991) Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke 22: 1276-1283.
12. Matsuo Y, Onodera H, Shiga Y, et al. (1994) Correlation between myeloperoxidase-quantified neutrophil accumulation and ischemic brain injury in the rat. Effects of neutrophil depletion. Stroke 25: 1469-1475.
13. Bednar MM, Raymond S, McAuliffe T, Lodge PA, Gross CE. (1991) The role of neutrophils and platelets in a rabbit model of thromboembolic stroke. Stroke 22: 44-50.
14. Winquist RJ, Kerr S. (1997) Cerebral ischemia-reperfusion injury and adhesion. Neurology 49(suppl 4): S23-S26.
15. x-glycosylated complement inhibitory protein. Science 285: 595-599.
16. Kato H, Kogure K, Liu XH, Araki T, Itoyama Y. (1996) Progressive expression of immunomolecules on activated microglia and invading leukocytes following focal cerebral ischemia in the rat. Brain. Res. 734: 203-212.
17. Okada Y, Copeland BR, Mori E, Tung MM, Thomas WS, del Zoppo GJ. (1994) P-selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion. Stroke 25: 202-211.
18. Hallenbeck JM. (1996) Significance of the inflammatory response in brain ischemia. Acta Neurochir. Suppl. 66: 27-31.
19. Zhang RL, Chopp M, Zaloga C, et al. (1995) The temporal profiles of ICAM-1 protein and mRNA expression after transient MCA occlusion in the rat. Brain Res. 682: 182-188.
20. Lindsberg PJ, Carpen O, Paetau A, Karjalainen-Lindsberg ML, Kaste M. (1996) Endothelial TCAM-1 expression associated with inflammatory cell response in human ischemic stroke. Circ. Res. 94: 939-945.
21. Kuroda S, Siesjo BK. (1997) Reperfusion damage following focal cerebral ischemia: pathophysiology and therapeutic windows. Clin. Neurosci. 4: 199-212.
22. Nishino H, Czurko A, Fukuda A, et al. (1994) Pathophysiological process after transient ischemia of the middle cerebral artery in the rat. Brain Res Bull 35: 51-56.
23. Jean WC Spellman SR, Nussbaum ES, Low WC. (1998) Reperfusion injury after focal cerebral ischemia: the role of inflammation and the therapeutic horizon. Neurosurgery 43: 1382-1397.
24. Bednar MM, Gross CE, Howard DB, Lynn M. (1997) Neutrophil activation in acute human central nervous system injury. Neurol. Res. 19: 588-592.
25. Wang X, Yue TL, Barone FC, White RF, Gagnon RC, Feuerstein GZ. (1994) Concomitant cortical expression of TNF-alpha and IL-1 beta mRNAs follows early response gene expression in transient focal ischemia. Molecular and Chemical Neuropathology 23: 103-114.
26. Kostulas N, Pelidou SH, Kivisakk P, Kostulas V, Link H. (1999) Increased IL-1beta, IL-8, and IL-17 mRNA expression in blood mononuclear cells observed in a prospective ischemic stroke study. Stroke 30: 2174-2179.
27. Relton JK, Rothwell NJ. (1992) Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res. Bull. 29: 243-246.
28. Casale TB, Carolan EJ. (1999) Combination of IL-8 plus TNF alpha induces additive neutrophil migration. Allergy Asthma Proc. 20: 361-363.
29. Nathan C. (1997) Inducible nitric oxide synthase: what difference does it make? [Review]. J. Clin. Invest 100: 2417-2423.
30. Iadecola C. (1997) Bright and dark sides of nitric oxide in ischemic brain injury. [Review]. Trends Neurosci. 20: 132-139.
31. Grandati M, Plotkine M, Verrecchia C, Revaud ML, Allix M, Boulu RG. (1997) Calcium-independent NO-synthase activity and nitrites/nitrates production in transient focal cerebral ischacmia in mice. Br. J. Pharmacol. 122: 625-630.
32. Iadecola C, Zhang F, Casey R, Clark HB, Ross ME. (1996) Inducible nitric oxide synthase gene expression in vascular cells after transient focal cerebral ischemia. Stroke 27: 1373-1380.
33. Iadecola C, Zhang F, Xu S, Casey R, Ross ME. (1995) Inducible nitric oxide synthase gene expression in brain following cerebral ischemia. J. Cereb. Blood Flow Metab. 15: 378-384.
34. Iadecola C, Xu X, Zhang F, el-Fakahany EE, Ross ME. (1995) Marked induction of calcium-independent nitric oxide synthase activity after focal cerebral ischemia. J. Cereb Blood Flow Metab. 15: 52-59.
35. Miettinen S, Fusco FR, Yrjanheikki J, et al. (1997) Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-D-aspartic acid-receptors and phospholipase A2. Proc. Natl. Acad Sci. U.S.A. 94: 6500-6505.
36. Nogawa S, Forster C, Zhang F, Nagayama M, Ross ME, Iadecola C. (1998) Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia. Proc. Natl. Acad. Sci. U.S.A. 95: 10966-10971.
37. Nogawa S, Zhang F, Ross ME, Iadecola C. (1997) Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J. Neurosci. 17: 2746-2755.
38. Planas AM, Soriano MA, Justicia C, Rodriguez-Farre E. (1999) Induction of cyclooxygenase-2 in the rat brain after a mild episode of focal ischemia without tissue inflammation or neural cell damage. Neurosci. Lett. 275: 141-144.
39. Iadecola C, Forster C, Nogawa S, Clark HB, Ross ME. (1999) Cyclooxygenase-2 immunoreactivity in the human brain following cerebral ischemia. Acta Neuropathol. 98: 9-14.
40. Nakayama M, Uchimura K, Zhu RL, et al. (1998) Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proc. Natl. Acad. Sci. U.S.A. 95: 10954-10959.
41. Connolly ES, Winfree CJ, Springer TA, et al. (1996) Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion: role of neutrophil adhesion in the pathogenesis of stroke. J. Clin. Invest. 97: 209-216.
42. Choudhri TF, Hoh BL, Zerwes H, et al. (1998) Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation. J Clin. Invest. 102: 1301-1310.
43. Ames A, Wright RL, Kowada M, Thurston JM, Majno G. (1968) Cerebral ischemia: the no-reflow phenomenon. Am. J. Pathol. 52: 437-453.
44. del Zoppo GJ, Hallenbeck JM. (2000) Advances in the vascular pathophysiology of ischemic stroke. Thromb. Res. 98: 73-81.
45. Kochanek PM, Hallenbeck JM. (1992) Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke 23: 1367-1379.
46. Matsuo Y, Onodera H, Shiga Y, et al. (1994) Role of cell adhesion molecules in brain injury after middle cerebral artery occlusion in the rat. Brain Res. 656: 344-352.
47. Hartl R, Schurer L, Schmid-Schonbein GW, del Zoppo GJ. (1996) Experimental antileukocyte interventions in cerebral ischemia. J. Cereb. Blood Flow Metab. 16: 1108-1119.
48. Prestigiacomo CJ, Kim SC, Connolly ES, Liao H, Van S, Pinsky DJ. (1999) CD18-mediated neutrophil recruitment contributes to the pathogenesis of reperfused but not non-reperfused stroke. Stroke 30: 1110-1117.
49. del Zoppo GJ. (1997) Microvascular responses to cerebral ischemia/inflammation. Ann. NY Acad. Sci. 823: 132-147.
50. del Zoppo GJ, von Kummer R, Hamann GF. (1998) Ischaemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke [editorial]. J. Neurol. Neurosurg. Psychiatry 65: 1-9.
51. Zhang RL, Chopp M, Chen H, Garcia JH. (1994) Temporal profile of ischemic tissue damage, neutrophil response, and vascular plugging following permanent and transient (2H) middle cerebral artery occlusion in the rat. J. Neurol. Sci. 125: 3-10.
52. Phillips JB, Williams AJ, Adams J, Elliot PJ, Tortella PC. (2000) Protease inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia. Stroke 31: 1686-1693.
53. Czermak BJ, Friedl HP, Ward PA. (1998) Complement, cytokines, and adhesion molecule expression in inflammatory reactions. [Review]. Proceedings of the Association of American Physicians 110: 306-312.
54. Murphy HS, Shayman JA, Till GO. (1991) Superoxide responses of endothelial cells to C5a and TNF-alpha: divergent signal transduction pathways. Am. J. Physiol. 263: L51-L59.
55. Peerschke EI, Reid KB, Ghebrehiwet B. (1993) Platelet activation by C1q results in the induction of alpha IIb/beta 3 integrins (GPIIb-IIIa) and the expression of P-selectin and procoagulant activity. J. Exp. Med. 178: 579-587.
56. Williams FM. (1996) Neutrophils and myocardial reperfusion injury. [Review]. Pharmacol. Ther. 72: 1-12.
57. Foreman KE, Vaporciyan AA, Bonish BK, et al. (1994) C5a-induced expression of P-selectin in endothelial cells. J. Clin Invest 94: 1147-1155.
58. Kilgore KS, Schmid E, Shanley TP. (1997) Sublytic concentrations of the membrane attack complex (MAC) of complement induce endothelial interleukin 8 (IL-8) and monocyte protein 1 (MCP-1) through nuclear factor-kB activation. Am. J. Pathol. 150: 2019-2031.
59. Kinoshita T. (1991) Biology of complement: the overture. Immunol. Today 12: 291-295.
60. Janeway C. (1999). Immunobiology: The immune system in health and disease. New York, Garland Publishing, pp. 339-358.
61. Frank MM, Fries LF. (1991) The role of complement in inflammation and phagocytosis. Immunol Today 12: 322-326.
62. Weisman HF, Bartow T, Leppo MK, et al. (1990) Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249: 146-151.
63. Bednar MM, Gross CE, Russell SR, Short D, Giclas PC. (2000) Activation of complement by tissue plasminogen activator, but not acute cerebral ischemia, in a rabbit model of thromboembolic stroke. J. Neurosurg. 86: 139-142.
64. Hays SJ. (1998) Therapeutic approaches to the treatment of neuroinflammatory diseases. [Review]. Current Pharmaceutical Design 4: 335-348.
65. Bartko D, Lesicky O, Buc M. (1997) [Cerebral infarct and the immune response]. [Slovak]. Bratisl Lek Listy 98: 321-329.
66. Thomas A, Gasque P, Vaudry D, Gonzalez B, Fontaine M. (2000) Expression of a complete and functional complement system by human neuronal cells in vitro. Int. Immunol. 12: 1015-1023.
67. Keller HU, Sorkin E. (1968) Chemotaxis of leukocytes. Experientia 24: 641-752.
68. Ward PA. (1970) Neutrophil chemotactic factors and related clinical disorders. Arthritis Rheum. 13: 181-186.
69. Muller-Eberhard HJ. (1968). Chemistry and reaction mechanisms of complement. In: Dixon FJ Jr, Kunkel HG, eds. Advances in Immunology. New York, Academic Press, pp. 1-80.
70. Ballow M, Cochrane CG. (1969) Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them. J. Immunol. 103: 944-952.
71. Klein PG, Wellensiek HJ. (1965) Multiple nature of the third component of guinea-pig complement. Immunology 8: 590-603.
72. Flexner S, Noguchi H. (1903) Snake venom in relation to hemolysis, bacteriolysis, and toxicity, J. Exp. Med. 6: 277-301.
73. Hill JH, Ward PA. (1969) C3 leukotactic fragments produced by tissue protease. J. Exp. Med. 130: 505.
74. Pinckard RN, Olson MS, Giclas PC, Terry R, Boyer JT, O'Rourke RA. (1975) Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction. J. Clin. Invest. 56: 740-750.
75. Rossen RD, Swain JL, Michael LH, Weakley S, Giannini E, Entman ML. (1985) Selective accumulation of the first component of complement and leukocytes in ischemic canine heart muscle: a possible initiator of an extra myocardial mechanism of ischemic injury. Circ. Res. 57: 119-130.
76. Vakeva A, Morgan BP, Tikkanen I, Helin K, Laurila P, Meri S. (1994) Time course of complement activation and inhibitor expression after ischemic injury of rat myocardium. Am. J. Pathol 144: 1357-1368.
77. McManus LM, Kolb WP, Crawford MH, O'Rourke RA, Grover FL, Pinckard RN. (1983) Complement localization in ischemic baboon myocardium. Lab. Invest 48: 436-447.
78. Pinckard RN, O'Rourke RA, Crawford MH, et al. (1980) Complement localization and mediation of ischemic injury in baboon myocardium. J. Clin. Invest. 66: 1050-1056.
79. Schafer H, Mathey D, Hugo F, Bhakdi S. (1986) Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium. J. Immunol. 137: 1945-1949.
80. Gibbs SA, Weiser MR, Kobzik L, Valeri CR, Shepro D, Hechtman HB. (1996) P-selectin mediates intestinal ischemic injury by enhancing complement deposition. Surgery 119: 652-656.
81. Kimura T, Andih A, Fujiyama Y, Saotome T, Bamba T. (1998) A blockade of complement activation prevents rapid intestinal ischemia-reperfusion injury by modulating mucosal mast cell degranulation in rats. Clin. Exp Immounol. 111: 484-490.
82. Dong J, Pratt JR, Smith RAG, Dodd I, Sacks SH. (1999) Strategies for targeting complement inhibitors in ischaemia/reperfusion injury. Mol. Immunol. 36: 957-963.
83. Rossen RD, Michael LH, Kagiyama A, et al. (1988) Mechanism of complement activation after coronary artery occlusion: evidence that myocardial ischemia in dogs causes release of constituents of myocardial subcellular origin that complex with human Clq in vivo. Circ. Res 62: 572-584.
84. Naka Y, Marsh HC, Scesney SM, Oz MC, Pinsky DJ. (1997) Complement activation as a cause for primary graft failure in an isogeneic rat model of hypothermic lung preservation and transplantation. Transplantation 64: 1248-1255.
85. Vakeva A, Laurila R, Meri S. (1992) Loss of expression of protectin (CD59) is associated with complement membrane attack complex deposition in myocardial infarction. Lab. Invest. 67: 608-616.
86. Hamilton KK, Ji Z, Rollins S, Stewart BH, Sims PJ. (1990) Regulatory control of the terminal component proteins at the surface of the human endothelial cells-neutralization of a C5b-9 inhibitor by antibody to CD59. Blood 76: 2572-2577.
87. Homeister JW, Satoh P, Lucchesi BR. (1992) Effects of complement activation in the isolated heart: role of the terminal complement components. Circ. Res. 71: 303-319.
88. Hattori R, Hamilton KK, McEver RP, Sims PJ. (1989) Complement proteins C5b-9 induce secretion of high molecular weight multimeters of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J. Biol. Chem. 264: 9053-9060.
89. Marsh JE, Pratt JR, Sacks SH. (1999) Targeting the complement system. Curr. Opin. Nephrol. Hypertens. 8: 557-562.
90. Vogel CW, Smith CA, Muller-Eberhard HJ. (1984) Cobra venom factor: structural homology with the third component of human complement. J. Immunol. 133: 3235-3241.
91. Maroko PR, Carpenter CB, Chariello M. (1978) Reduction by Cobra Venom Factor of myocardial necrosis after coronary artery occlusion. J Clin. Invest. 61: 661-670.
92. Crawford MH, Grover FL, Kolb WP, et al. (1988) Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury. Circulation 78: 1449-1458.
93. Maclean D, Fishbein MC, Braunwald E, Maroko PR. (1978) Long-term preservation of ischemic myocardium after experimental coronary artery occlusion. J. Clin Invest. 61: 541-551.
94. Ren XD, Huang SJ, Sun JJ, Zhu ZG. (1994) Protective effect of cobra venom factor on pulmonary injury induced by oleic acid. Int. J Immunopharmacol. 16: 969-975.
95. Dehring DJ, Steinberg SM, Wismar BL, Lowery BD, Carey LC, Cloutier CT. (1987) Complement depletion in a porcine model of septic acute respiratory disease. J. Trauma 27: 615- 625.
96. Candinas D, Lesnikoski BA, Robson SC, et al. (1996) Effect of repetitive high dose treatment with soluble complement receptor 1 and cobra venom factor on discordant xenograft survival. Transplantation 62: 336-342.
97. Lazar HL, Hamasaki T, Bao Y, Rivers S, Bernard SA, Shemin RJ. (1998) Soluble complement receptor type I limits damage during revascularization of ischemic myocardium. Ann. Thorac Surg 65: 973-977.
98. Homeister JW, Lucchesi BR. (1994) Complement activation and inhibition in myocardial ischemia and reperfusion injury. Annu. Rev Pharmacol Toxicol. 34: 17-40.
99. Jaeschke H, Farhood A, Bautista AP, Spolarics Z, Spitzer JJ. (1993) Complement activates Kupffer cells and neutrophils during reperfusion after hepatic ischemia. Am. J. Physiol. 264: G801-G809.
100. Amsterdam EA, Stahl GL, Pan H-L, Rendig SV, Fletcher MP, Longhurst JC. (1995) Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J. Physiol Heart Circ. Physiol. 268: H448-H457.
101. Vakeva A, Agah A, Rollins SA, Matis LA, Li L, Stahl GL. (1998) Myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Role of terminal complement components and inhibition by anti-C5 therapy. Circulation 97: 2259-2267.
102. Hopken U, Mohr M, Struber A, et al. (1996) Inhibition of interleukin-6 synthesis in an animal model of septic shock by anti-C5a monoclonal antibodies. Eur. J Immunol. 26: 1103-1109.
103. Fitch JC, Rollins S, Matis L, et al. (1999) Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass . Circulation 100: 2499-2506.
104. Weiser MR, Williams JP, Moore FD Jr, et al. (1996) Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J. Exp. Med. 183: 2343-2348.
105. Kilgore KS, Park JL, Tanheco EJ, Booth EA, Marks RM, Lucchesi BR. (1998) Attenuation of interleukin-8 expression in Co-deficient rabbits after myocardial ischemia/reperfusion. J. Mol. Cell Cardiol. 30: 75-85.
106. Ito W, Schafer HJ, Bhakdi S, et al. (1996) Influence of the terminal complement-complex on reperfusion injury, noreflow and arrythmias: a comparison between C6-competent and Co-deficient rabbits. Cardiovasc. Res. 32: 294-305.
107. Thielens NM, Bersch B, Hernandez J, Arluad GJ. (1999) Structure and functions of the interaction domains of C1r and C1s: keystones of the architecture of the C1 complex. Immunopharmacology 42: 3-13.
108. Lorincz Z, Gal P, Dobo J, et al. (2000) The cleavage of two C1s subunits by a single active C1r reveals substantial flexibility of the C1s-C1r-C1r-C1s tetramer in the C1 complex. J Immunol. 165: 2048-2051.
109. Buerke M, Murohara T, Lefer AM. (1995) Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation 91: 393-402.
110. Murohara T, Guo JP, Delyani JA, Lefer AM. (1995) Cardio-protective effects of selective inhibition of the two complement activation pathways in myocardial ischemia and reperfusion injury. Methods Find. Exp. Clin. Pharmacol. 17: 499-507.
111. Buerke M, Prufer D, Dahm M, Oelert H, Meyer J, Darius H. (1998) Blocking of classical complement pathway inhibits endothelial adhesion molecule expression and preserves ischemic myocardium from reperfusion injury. J. Pharmacol. Exp. Ther. 286: 429-438.
112. Barnum SR. (1999) Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) disease. [Review]. Mol Med. 5: 569-582.
113. Gasque P, Singhrao SK, Neal JW, Gotze O, Morgan BP. (1997) Expression of the receptor for Complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am. J. Pathol. 150: 31-41.
114. Ostergaard JR, Kristensen BO, Svehag S, Teisner B, Miletic T. (1987) Immune complexes and complement activation following rupture of intracranial saccular aneurysms. J. Neurosurg. 66: 891-897.
115. Hidetoshi K, Takashi S. (1989) Activated complement components C3a and C4a in cerebrospinal fluid and plasma following subarachnoid hemorrhage. J. Neurosurg. 71: 741-746.
116. Lindsberg PJ, Ohman J, Lehto T, et al. (1996) Complement activation in the central nervous system following blood-brain barrier damage in man. Ann. Neurol 40: 587-596.
117. German JW, Gross CE, Giclas P, Watral W, Bednar MM. (1996) Systemic complement depletion inhibits experimental cerebral vasospasm. Neurosurgery 39: 141-15.
118. Kaczorowski SL, Schiding JK, Toth CA, Kochanek PM. (1995) Effect of soluble complement receptor-1 on neutrophil accumulation after traumatic brain injury in rats. J. Cereb. Blood Flow Metab. 15: 860-864.
119. Velazquez P, Cribbs DH, Poulos TL, Tenner AJ. (1997) Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis. Nat. Med. 3: 77-79.
120. Afagh A, Cummings BJ, Cribbs DH, Cotman CW, Tenner AJ. (1996) Localization and cell association of C1q in Alzheimer's disease brain. Exp. Neurol. 138: 22-32.
121. McGeer PL, Akiyama H, Itagaki S, McGeer EG. (1989) Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci. Lett. 107: 341-346.
122. Wren DR, Noble M. (1989) Oligodendrocytes and oligo-dendrocyte/type-2 astrocyte progenitor cells of adult rats are specifically susceptible to the lytic effects of complement in absence of antibody. Proc. Natl. Acad Sci. USA 86: 9025-9029.
123. Cyong J, Witkin SS, Rieger B, Barbarese E, Good RA, Day NK. (1982) Antibody-independent complement activation by myelin via the classical complement pathway. J. Exp. Med. 155: 587-598.
124. Sanders ME, Koski CL, Robbins D, Shin ML, Frank MM, Joiner KA. (1986) Activated terminal complement in cerebrospinal fluid in Guillain-Barre syndrome and multiple sclerosis. J. Immunol. 136: 4456-4459.
125. Albrecht P. (1978) Immune control in experimental subacute sclerosing panencephalitis. Am. J. Clin. Pathol. 170: 175.
126. Schafer MK, Schwaeble WJ, Post C, et al. (2000) Complement Clq is dramatically up-regulated in brain microglia in response to transient global cerebral ischemia. J. Immunol. 164: 5446-5452.
127. Spiegel K, Emmerling MR, Barnum SR. (1997). Inflammatory mechanisms and management of neurodegeneration. Totowa, NJ, Humana Press, pp. 129-176.
128. Morgan BP, Gasque P, Singhrao S, Piddlesden SJ. (1997) The role of complement in disorders of the nervous system. Immunopharmacology 38: 43-50.
129. Nataf S, Stahel PF, Davoust N, Barnum SR. (1999) Complement anaphylatoxin receptor expression on neurons: new tricks for old receptors? Trends Neurosci. 22: 397-402.
130. McGeer PL, McGeer EG. (1999) Inflammation of the brain in Alzheimer's disease: implications for therapy. J. Leukoc. Biol. 65: 409-415.
131. Scolding NJ, Morgan BP, Compston DA. (1998) The expression of complement regulatory proteins by adult human oligodendrocytes. J. Neuroimmunol. 84: 69-75.
132. Gasque P, Singhrao SK, Neal JW. (1998) The anaphylatoxin receptor for complement C3a is expressed by rat oligodendrocytes. Role in cell chemotaxis and cell activation. J. Neuroimmunol. 90: 21 A.
133. Klegeris A, Bissonnette CJ, Dorovini-Zis K, McGeer PL. (2000) Expression of complement messenger RNAs by human endothelial cells. Brain Res. 871: 1-6.
134. Johnson SA, Lampert-Etchells M, Pasinetti CM, Rozovsky I, Finch CE. (1992) Complement mRNA in the mammalian brain: responses to Alzheimer's disease and experimental brain lesioning. Neurobiol Aging 13: 641-648.
135. Pasinetti CM, Johnson SA, Rozovsky I, et al. (1992) Complement C1qB and C4 mRNAs responses to lesioning in rat brain. Exp. Neurol. 118: 117-125.
136. Van Beek J, Bernaudin M, Petit E, et al. (2000) Expression of receptors for complement anaphylatoxins C3a and C5a following permanent focal cerebral ischemia in the mouse. Exp Neurol 161: 373-382.
137. Robinson AP, White TM, Mason DW. (1986) Macrophage heterogeneity in the rat as delineated by two monoclonal antibodies MRC Ox-41 and MRC Ox-42, the later recognizing complement receptor type 3. Immunology 57: 239-247.
138. Tohgi H, Utsugisawa K, Nagane Y. (2000) Hypoxia-induced expression of C1q, a subcomponent of the complement system, in cultured rat PC12 cells. Neurosci. Lett 291: 151-154.
139. Van Beek J, Chan P, Bernaudin M, Petit E, Mackenzie ET, Fontaine M. (2000) Glial responses, clusterin, and complement in permanent focal cerebral ischemia in the mouse. Glia 31: 39-50.
140. Vasthare US, Barone FC, Sarau HM, et al. (1998) Complement depletion improves neurological function in cerebral ischemia. Brain Res. Bull. 45: 413-419.
141. Lew SM, Gross CE, Bednar MM, et al. (1999) Complement depletion does not reduce brain injury in a rabbit model of thromboembolic stroke. Brain Res. Bull. 48: 325-331.
142. Webster SD, Park M, Fonseca MI, Tenner AJ. (2000) Structural and functional evidence for microglial expression of C1qR(P), the C1q receptor that enhances phagcytosis. J. Leukoc. Biol 67: 109-116.
143. Nepomuceno RR, Henschen-Edman AH, Burgess WH, Tenner AJ. (1997) cDNA cloning and primary structure analysis of C1qR(P), the human C1q/MBL/SPA receptor that mediates enhanced phagocytosis in vitro. Immunity 6: 119-129.
144. Rittershaus CW, Thomas LJ, Miller DP, et al. (1999) Recombinant glycoproteins which inhibit complement activation and also bind the selectin adhesion molecule. J. Biol. Chem. 274: 11237-11244.